Sign in

    Resmed Inc (RMD)

    You might also like

    ResMed Inc. is a global leader in digital health and cloud-connected medical devices, focusing on treating and managing respiratory disorders such as sleep apnea and chronic obstructive pulmonary disease (COPD), as well as other chronic diseases . The company designs innovative solutions to improve patient quality of life, reduce the impact of chronic disease, and lower healthcare costs by shifting care from hospitals to home settings . ResMed's product lines include medical devices like CPAP systems, mask systems, diagnostic products, and cloud-based software applications for connected care .

    1. Masks, Diagnostic Products, and Accessories - Develops and markets a range of masks, diagnostic tools, and accessories essential for the treatment and management of respiratory disorders.
    2. Software as a Service (SaaS) - Offers out-of-hospital software platforms that support healthcare providers in managing patient care outside of hospitals, enhancing operational efficiencies and patient outcomes.
    3. CPAP Systems - Provides continuous positive airway pressure (CPAP) systems designed to treat sleep apnea and improve patient breathing during sleep.
    4. Cloud-Based Software Applications - Delivers connected care solutions through cloud-based software, facilitating remote monitoring and management of patient health data.
    NamePositionStart DateShort Bio
    Michael "Mick" FarrellChairman of the Board and CEOMarch 2013 (CEO), January 2023 (Chairman)Michael "Mick" Farrell has been serving as the Chief Executive Officer and a director of ResMed Inc. since March 2013. He was appointed as the Chairman of the Board in January 2023. Mr. Farrell joined ResMed in 2000 and has held various leadership roles, including President of the Americas region from 2011 to 2013 .
    Bobby GhoshalChief Commercial Officer, SaaSNovember 2023Bobby Ghoshal was appointed as the Chief Commercial Officer, SaaS at ResMed in November 2023. Prior to this role, he served as the President of ResMed's SaaS business from September 2021 to November 2023 .
    Justin LeongChief Product OfficerNovember 2023Justin Leong was appointed as the Chief Product Officer of ResMed in November 2023. Prior to this role, he held progressively increasing responsibilities for ResMed's Asian and Latin American markets from 2018 to 2023 .
    Michael "Mike" RiderGlobal General Counsel and SecretaryJuly 1, 2023Michael "Mike" Rider was appointed as the Global General Counsel and Secretary of ResMed effective July 1, 2023. Prior to this role, he served as ResMed's senior vice president, deputy global general counsel, and legal business partner for ResMed's sleep and respiratory care team from July 2019 through June 2023 .
    Brett SandercockChief Financial OfficerJanuary 2006Brett Sandercock has been serving as the Chief Financial Officer of ResMed since January 2006. Prior to this role, he was ResMed's Vice President of Treasury and Finance from November 2004 until December 2005 .
    Christopher DelOreficeBoard Member and Audit Committee MemberAugust 15, 2024Christopher DelOrefice is a Board Member and Audit Committee Member at ResMed Inc. (RMD). He was elected to the board during the August 15, 2024 board meeting and appointed to the audit committee. DelOrefice is a seasoned financial executive with extensive experience in the medical technology industry .
    1. Given your expansion into adjacent areas like insomnia and COPD, can you elaborate on how you plan to effectively compete in these markets and what specific investments you're making to ensure growth in these areas?
    2. With major consumer tech companies like Apple and Samsung entering the sleep apnea detection space, how do you intend to differentiate ResMed's offerings to capture the potential increase in patient demand and prevent possible disruptions to your traditional business model?
    3. Considering the price increases implemented last year due to supply chain challenges, what is your pricing strategy moving forward, and how do you anticipate this will impact your relationships with customers and your competitive position in the market?
    4. Despite increasing production capacity for the AirSense 11, you mentioned there might still be a backlog of patients waiting for this device; what challenges are you facing in fully meeting the demand, and how might this impact your market share if competitors fulfill orders more promptly?
    5. Your recent "tuck-in" acquisitions like Snap Technologies, Somnoware, and NightOwl have added new capabilities; can you clarify your M&A strategy going forward, specifically regarding the scale of acquisitions you're considering and how you plan to balance these investments with capital management as your free cash flow increases?
    Program DetailsProgram 1
    Approval DateFebruary 21, 2014
    End Date/DurationNo specified end date
    Total additional amount20.0 million shares
    Remaining authorization amount11.8 million shares (as of 2024-12-21)
    DetailsThe program may be accelerated, suspended, delayed, or discontinued at any time at the discretion of the board of directors
    YearAmount Due (Millions)Debt TypeInterest Rate (%)% of Total Debt
    2026250.0 Senior Notes3.24 37.2% = (250 / 672.765) * 100
    2027N/ARevolving & Term Credit Agreement5.2 N/A
    2029250.0 Senior Notes3.45 37.2% = (250 / 672.765) * 100

    Competitors mentioned in the company's latest 10K filing.

    • Philips BV; ongoing product recall may impact ResMed's business
    • Fisher & Paykel Healthcare Corporation Limited
    • DeVilbiss Healthcare
    • Apex Medical Corporation
    • BMC Medical Co. Ltd.
    • React Health Corporation
    • Lowenstein
    NameStart DateEnd DateReason for Change
    KPMG LLP1994 PresentCurrent auditor

    Recent developments and announcements about RMD.

    Financial Reporting

      Earnings Call

      ·
      5 days ago

      ResMed recently released its earnings call transcript for the second quarter of fiscal year 2025, highlighting several key points:

      • Financial Performance: ResMed reported a 10% increase in global revenue, driven by strong performance across its sleep health, breathing health, and residential care software portfolios. The company achieved a 230 basis point increase in gross margin to 59.2% and a 29% increase in non-GAAP earnings per share.

      • Revenue and Profit: The company saw a 19% increase in operating profit, supported by revenue growth and gross margin expansion. Net income for the quarter increased by 29%, with cash flow from operations at $309 million.

      • Market Performance: Device sales grew by double digits, with strong demand for the AirSense 10 and AirSense 11 platforms. The Masks and Accessories business also experienced double-digit growth.

      • Forward Guidance: Management expects gross margins to remain in the range of 59% to 60% for the second half of fiscal year 2025. They are also focusing on strategic investments in R&D and SG&A to drive sustainable growth.

      • Strategic Initiatives: ResMed is expanding its AirSense 11 platform globally and investing in technology and infrastructure to improve supply chain efficiencies. The company is also focusing on digital health solutions and leveraging AI to enhance patient care.

      • Analyst Questions: Analysts inquired about gross margin guidance, market growth versus company growth, and the impact of GLP-1 medications on patient flow. Management highlighted ongoing initiatives to optimize manufacturing and procurement, as well as the potential for increased patient flow from new pharmaceutical and consumer tech trends.

      • Market Conditions: ResMed is well-positioned to benefit from increasing awareness and demand for sleep health solutions, driven by both pharmaceutical advancements and consumer technology integrations.

      Overall, ResMed's strong financial performance and strategic initiatives indicate a positive outlook for the remainder of fiscal year 2025, with continued focus on innovation and market expansion.

      Earnings Report

      ·
      5 days ago

      ResMed Inc. (RMD) Second Quarter 2025 Earnings Results

      ResMed Inc. has released its earnings results for the second quarter of fiscal year 2025, ending December 31, 2024. Below are the key highlights:

      Financial Performance

      • Revenue: $1.3 billion, a 10% increase year-over-year, driven by strong demand for sleep devices, masks, and growth in the Residential Care Software business.
      • Net Income: $344.6 million, a 65% increase compared to the prior year.
      • Diluted Earnings Per Share (EPS): $2.34, up 65%; Non-GAAP diluted EPS was $2.43, a 29% increase.
      • Operating Cash Flow: $309 million, reflecting strong cash generation.

      Operational Highlights

      • Gross Margin: Improved by 300 basis points to 58.6%, attributed to manufacturing efficiencies and lower component costs. Non-GAAP gross margin increased by 230 basis points to 59.2%.
      • Regional Revenue Growth:
        • U.S., Canada, and Latin America: Revenue grew by 12%.
        • Europe, Asia, and Other Markets: Revenue increased by 8% on a constant currency basis.
      • Residential Care Software: Revenue increased by 8%, reflecting continued organic growth.

      Capital Management

      • Dividends: Declared a quarterly cash dividend of $0.53 per share, payable on March 20, 2025, with a record date of February 13, 2025.
      • Share Repurchase: Repurchased 307,000 shares for $75 million during the quarter.

      CEO Commentary

      Mick Farrell, Chairman and CEO, highlighted the company's focus on operational excellence and its ability to capitalize on opportunities in digital health and sleep health solutions. He emphasized the company's strong market position and commitment to innovation.

      Future Outlook

      ResMed continues to invest in its global operations, including expanding its Singapore facilities, and remains focused on leveraging advancements in digital health and consumer wearables to drive growth.

      For more details, the full earnings webcast is available on ResMed's Investor Relations website.